levetiracetam and Neoplasm-Regression--Spontaneous

levetiracetam has been researched along with Neoplasm-Regression--Spontaneous* in 1 studies

Other Studies

1 other study(ies) available for levetiracetam and Neoplasm-Regression--Spontaneous

Article	Year
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. BMJ case reports, 2016, Dec-23, Volume: 2016 Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14.6 months by maximal safe resection with radiation and temozolamide. In the absence of chemotherapy, radiotherapy or chemoradiotherapy, spontaneous regression of GBM or regression while only being on dexamethasone (DEX) and levetiracetam (LEV) have seldom been reported. Here, we present a case of a patient who had significant regression of the GBM with DEX and LEV alone. In this study, we hypothesise a plausible antineoplastic role of DEX and or LEV in GBM and highlight molecular, preclinical and clinical studies supporting this role. Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; Dacarbazine; Dexamethasone; Glioblastoma; Humans; Levetiracetam; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Regression, Spontaneous; Neoplasms, Second Primary; Piracetam; Temozolomide	2016

Article

Year

Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.

BMJ case reports, 2016, Dec-23, Volume: 2016

Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14.6 months by maximal safe resection with radiation and temozolamide. In the absence of chemotherapy, radiotherapy or chemoradiotherapy, spontaneous regression of GBM or regression while only being on dexamethasone (DEX) and levetiracetam (LEV) have seldom been reported. Here, we present a case of a patient who had significant regression of the GBM with DEX and LEV alone. In this study, we hypothesise a plausible antineoplastic role of DEX and or LEV in GBM and highlight molecular, preclinical and clinical studies supporting this role.

Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; Dacarbazine; Dexamethasone; Glioblastoma; Humans; Levetiracetam; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Regression, Spontaneous; Neoplasms, Second Primary; Piracetam; Temozolomide

2016